Shots:
- Merck initiates the P-IIb/III (MALBEC) trial assessing MK-8748 (Tiespectus/EYE201) for the treatment of neovascular (wet) age-related macular degeneration (NVAMD)
- The trial will assess the safety & efficacy of two intravitreal dose levels of MK-8748 vs aflibercept (2mg), with Q4W dosing initially for 3mos., then Q8W through Wk. 48, followed by individualized dosing intervals, with the last study visit at Wk. 96
- The MALBEC study is the first pivotal trial in the late-phase program for MK-8748, with a second NVAMD study planned to begin this year, based on P-I/IIa (RIOJA) results evaluating MK-8748 in NVAMD, macular edema secondary to branch retinal vein occlusion or diabetic macular edema
Ref: Merck | Image: Merck | Press Release
Related News: Merck Receives the EC Approval for Keytruda, Plus CT ± Avastin to Treat PD-L1+ Pt-Resistant Ovarian Carcinoma
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
